Interleukin-10-Producing DC-10 Is a Unique Tool to Promote Tolerance Antigen-Specific T Regulatory Type 1 Cells

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Apr 25

PMID 29686676

Citations 39

Authors

Michela Comi

Giada Amodio

Silvia Gregori

Affiliations

Soon will be listed here.

Abstract

The prominent role of tolerogenic dendritic cells (tolDCs) in promoting immune tolerance and the development of efficient methods to generate clinical grade products allow the application of tolDCs as cell-based approach to dampen antigen (Ag)-specific T cell responses in autoimmunity and transplantation. Interleukin (IL)-10 potently modulates the differentiation and functions of myeloid cells. Our group contributed to the identification of IL-10 as key factor in inducing a subset of human tolDCs, named dendritic cell (DC)-10, endowed with the ability to spontaneously release IL-10 and induce Ag-specific T regulatory type 1 (Tr1) cells. We will provide an overview on the role of IL-10 in modulating myeloid cells and in promoting DC-10. Moreover, we will discuss the clinical application of DC-10 as inducers of Ag-specific Tr1 cells for tailoring Tr1-based cell therapy, and as cell product for promoting and restoring tolerance in T-cell-mediated diseases.

Citing Articles

The Contribution of Genetic and Epigenetic Factors: An Emerging Concept in the Assessment and Prognosis of Inflammatory Bowel Diseases.

Minea H, Singeap A, Minea M, Juncu S, Muzica C, Sfarti C Int J Mol Sci. 2024; 25(15).

PMID: 39125988 PMC: 11313574. DOI: 10.3390/ijms25158420.

Invariant NKT cells are more abundant in peanut-allergic adults and a subset of CD8 iNKT cells are depleted after peanut oil exposure.

Hopkins G, Cochrane S, Onion D, Fairclough L Front Immunol. 2023; 14:1293158.

PMID: 38022648 PMC: 10655100. DOI: 10.3389/fimmu.2023.1293158.

Tolerogenic dendritic cells generated using a novel protocol mimicking mucosal tolerance mechanisms represent a potential therapeutic cell platform for induction of immune tolerance.

Dao Nyesiga G, Pool L, Englezou P, Hylander T, Ohlsson L, Appelgren D Front Immunol. 2023; 14:1045183.

PMID: 37901231 PMC: 10613069. DOI: 10.3389/fimmu.2023.1045183.

Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio.

Laux J, Martorelli M, Spath N, Maier F, Burnet M, Laufer S ACS Pharmacol Transl Sci. 2023; 6(6):892-906.

PMID: 37325444 PMC: 10262334. DOI: 10.1021/acsptsci.3c00043.

Mesenchymal Stem Cells Suppress Dendritic Cells and Modulate Proinflammatory Milieu Through Interleukin-10 Expression in Peripheral Blood Mononuclear Cells of Human Systemic Lupus Erythematosus.

Darlan D, Raga A, Muradi Muhar A, Putra A, Alif I Acta Inform Med. 2023; 31(1):20-25.

PMID: 37038492 PMC: 10082662. DOI: 10.5455/aim.2023.31.20-25.

References

Sheedy F, Palsson-McDermott E, Hennessy E, Martin C, OLeary J, Ruan Q . Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2009; 11(2):141-7. DOI: 10.1038/ni.1828. View

Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius A . Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol. 2003; 135(1):64-73. PMC: 1808913. DOI: 10.1111/j.1365-2249.2004.02342.x. View

Murray P . Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol. 2006; 6(4):379-86. DOI: 10.1016/j.coph.2006.01.010. View

Verma R, Balakrishnan L, Sharma K, Khan A, Advani J, Gowda H . A network map of Interleukin-10 signaling pathway. J Cell Commun Signal. 2015; 10(1):61-7. PMC: 4850137. DOI: 10.1007/s12079-015-0302-x. View

Amodio G, Gregori S . Human tolerogenic DC-10: perspectives for clinical applications. Transplant Res. 2013; 1(1):14. PMC: 3560992. DOI: 10.1186/2047-1440-1-14. View

Berlato C, Cassatella M, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F . Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol. 2002; 168(12):6404-11. DOI: 10.4049/jimmunol.168.12.6404. View

Groux H, Cottrez F . The complex role of interleukin-10 in autoimmunity. J Autoimmun. 2003; 20(4):281-5. DOI: 10.1016/s0896-8411(03)00044-1. View

Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J . A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1998; 186(11):1809-18. PMC: 2199153. DOI: 10.1084/jem.186.11.1809. View

Williams L, Bradley L, Smith A, Foxwell B . Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol. 2003; 172(1):567-76. DOI: 10.4049/jimmunol.172.1.567. View

10.

Saraiva M, Christensen J, Veldhoen M, Murphy T, Murphy K, OGarra A . Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity. 2009; 31(2):209-19. PMC: 2791889. DOI: 10.1016/j.immuni.2009.05.012. View

11.

Chen Q, Daniel V, Maher D, Hersey P . Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer. 1994; 56(5):755-60. DOI: 10.1002/ijc.2910560524. View

12.

Wessells J, Baer M, Young H, Claudio E, Brown K, Siebenlist U . BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem. 2004; 279(48):49995-50003. DOI: 10.1074/jbc.M404246200. View

13.

Gagliani N, Magnani C, Huber S, Gianolini M, Pala M, Licona-Limon P . Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013; 19(6):739-46. DOI: 10.1038/nm.3179. View

14.

Hutchins A, Diez D, Miranda-Saavedra D . The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics. 2013; 12(6):489-98. PMC: 3838198. DOI: 10.1093/bfgp/elt028. View

15.

Kobayashi T, Matsuoka K, Sheikh S, Elloumi H, Kamada N, Hisamatsu T . NFIL3 is a regulator of IL-12 p40 in macrophages and mucosal immunity. J Immunol. 2011; 186(8):4649-55. PMC: 3172700. DOI: 10.4049/jimmunol.1003888. View

16.

Chauveau C, Remy S, Royer P, Hill M, Tanguy-Royer S, Hubert F . Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood. 2005; 106(5):1694-702. DOI: 10.1182/blood-2005-02-0494. View

17.

Naranjo-Gomez M, Raich-Regue D, Onate C, Grau-Lopez L, Ramo-Tello C, Pujol-Borrell R . Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med. 2011; 9:89. PMC: 3141500. DOI: 10.1186/1479-5876-9-89. View

18.

Mosser D, Zhang X . Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2009; 226:205-18. PMC: 2724982. DOI: 10.1111/j.1600-065X.2008.00706.x. View

19.

Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani C . Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 2010; 116(6):935-44. DOI: 10.1182/blood-2009-07-234872. View

20.

Yasukawa H, Sasaki A, Yoshimura A . Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000; 18:143-64. DOI: 10.1146/annurev.immunol.18.1.143. View